Drug Approval | October 01, 2025
Lupin receives FDA approval Rivaroxaban for oral suspension
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
India currently hosts more than 10,075 biotech startups
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Miels will formally assume the role on January 1, 2026
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
The platform is being introduced to expand access to treatments for people living with chronic conditions
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Subscribe To Our Newsletter & Stay Updated
